A 14‐Year Study of Serum Glial Fibrillary Acidic Protein and Total Tau in Premanifest Huntington's
There is a pressing need for blood biomarkers that can identify Huntington's disease (HD) gene carriers' proximity to manifest disease. We previously examined serial serum neurofilament light (NfL) concentrations in 21 premanifest HD gene carriers and 14 controls over 14 years, finding that NfL demonstrates high prognostic value and distinct longitudinal dynamics in premanifest/transitional HD. Here, we report the corresponding results for serum glial fibrillary acidic protein and total tau, providing the first longitudinal and head-to-head study of these biomarkers in HD. Our findings do not support the utility of these analytes as prognostic biomarkers in premanifest and transitional HD.
Authors
- Zanna J. Voysey (ORCID: https://orcid.org/0000-0002-6980-6059)
- Maura Malpetti (ORCID: https://orcid.org/0000-0001-8923-9656)
- Alpár S. Lázár (ORCID: https://orcid.org/0000-0003-3147-8229)
- Lennart R. B. Spindler
- Jonathan Holbrook (ORCID: https://orcid.org/0000-0001-8660-0282)
- Roger A. Barker (ORCID: https://orcid.org/0000-0001-8843-7730)
- Anna Goodman (ORCID: https://orcid.org/0000-0001-9995-6659)
- Natalia E. Owen (ORCID: https://orcid.org/0009-0008-0089-9120)
- Clara Le Draoulec
Institutions
- University of East Anglia (GB)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- University of Cambridge (GB)
- UK Dementia Research Institute (GB)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1002/acn3.70057
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- UK Research and Innovation
- National Institute for Health and Care Research
- Guarantors of Brain
- Alzheimer’s Research UK
- Medical Research Council
- NIHR Cambridge Biomedical Research Centre